Takeaways Sobi’s Empaveli is now positioned to move from import‑only, limited‑access status into publicly funded, pan‑Canadian treatment for C3 glomerulopathy and primary IC‑MPGN, one ...
Takeaways: The positive recommendation from CDA-AMC, backed by Phase III BE HEARD I and II trials, should accelerate payer negotiations and improve access for patients with chronic, pa...
